Treatment of primary biliary cirrhosis

Bibliography

• Prince MI, James OF. The epidemiology of primary biliary cirrhosis. Clin Liver Dis 2003;7:795-819
   PubMedGoogle Scholar
• Hirschfield GM, Liu X, Xu C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009;360:2544-55
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Chapman RW, Karlsen TH, et al. The genetics of complex cholestatic disorders. Gastroenterology 2013;144:1357-74
   PubMed Web of Science ®Google Scholar
• Poupon R, Ping C, Chretien Y, et al. Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J Hepatol 2008;49:1038-45
   PubMed Web of Science ®Google Scholar
• Corpechot C, Chretien Y, Chazouilleres O, Poupon R. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol 2010;53:162-9
   PubMed Web of Science ®Google Scholar
• Corpechot C, Gaouar F, Chretien Y, et al. Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. J Hepatol 2012;56:218-24
   PubMed Web of Science ®Google Scholar
• Corpechot C, Barbu V, Chazouilleres O, Poupon R. Fetal microchimerism in primary biliary cirrhosis. J Hepatol 2000;33:696-700
   PubMed Web of Science ®Google Scholar
• Invernizzi P, De Andreis C, Sirchia SM, et al. Blood fetal microchimerism in primary biliary cirrhosis. Clin Exp Immunol 2000;122:418-22
   PubMed Web of Science ®Google Scholar
• Invernizzi P, Miozzo M, Battezzati PM, et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet 2004;363:533-5
   PubMed Web of Science ®Google Scholar
• Odin JA, Huebert RC, Casciola-Rosen L, et al. Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis. J Clin Invest 2001;108:223-32
   PubMed Web of Science ®Google Scholar
• Allina J, Hu B, Sullivan DM, et al. T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun 2006;27:232-41
   PubMed Web of Science ®Google Scholar
• Tsuneyama K, Van de Water J, Leung PS, et al. Abnormal expression of the E2 component of the pyruvate dehydrogenase complex on the luminal surface of biliary epithelium occurs before major histocompatibility complex class II and BB1/B7 expression. Hepatology 1995;21:1031-7
   PubMed Web of Science ®Google Scholar
• Matsumura S, Van De Water J, Leung P, et al. Caspase induction by IgA antimitochondrial antibody: IgA-mediated biliary injury in primary biliary cirrhosis. Hepatology 2004;39:1415-22
   PubMed Web of Science ®Google Scholar
• Afford SC, Ahmed-Choudhury J, Randhawa S, et al. CD40 activation-induced, Fas-dependent apoptosis and NF-kappaB/AP-1 signaling in human intrahepatic biliary epithelial cells. FASEB J 2001;15:2345-54
   PubMed Web of Science ®Google Scholar
• Popper H, Paronetto F, Schaffner F. Immune processes in the pathogenesis of liver disease. Ann NY Acad Sci 1965;124:781-99
   PubMed Web of Science ®Google Scholar
• Portmann B, Popper H, Neuberger J, Williams R. Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 209 patients. Gastroenterology 1985;88:1777-90
   PubMed Web of Science ®Google Scholar
• Nakanuma Y, Saito K, Unoura M. Semiquantitative assessment of cholestasis and lymphocytic piecemeal necrosis in primary biliary cirrhosis: a histologic and immunohistochemical study. J Clin Gastroenterol 1990;12:357-62
   PubMed Web of Science ®Google Scholar
• Melero S, Spirli C, Zsembery A, et al. Defective regulation of cholangiocyte Cl-/HCO3(-) and Na+/H+ exchanger activities in primary biliary cirrhosis. Hepatology 2002;35:1513-21
   PubMed Web of Science ®Google Scholar
• Medina JF, Martinez A, Vazquez JJ, Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology 1997;25:12-17
   PubMed Web of Science ®Google Scholar
• Shibao K, Hirata K, Robert ME, Nathanson MH. Loss of inositol 1,4,5-trisphosphate receptors from bile duct epithelia is a common event in cholestasis. Gastroenterology 2003;125:1175-87
   PubMed Web of Science ®Google Scholar
• Spirli C, Nathanson MH, Fiorotto R, et al. Proinflammatory cytokines inhibit secretion in rat bile duct epithelium. Gastroenterology 2001;121:156-69
   PubMed Web of Science ®Google Scholar
• Spirli C, Fabris L, Duner E, et al. Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology 2003;124:737-53
   PubMed Web of Science ®Google Scholar
• Prieto J, Garcia N, Marti-Climent JM, et al. Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology 1999;117:167-72
   PubMed Web of Science ®Google Scholar
• Christensen E, Crowe J, Doniach D, et al. Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 1980;78:236-46
   PubMed Web of Science ®Google Scholar
• Prince M, Chetwynd A, Newman W, et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002;123:1044-51
   PubMed Web of Science ®Google Scholar
• Angulo P, Lindor KD, Therneau TM, et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 1999;19:115-21
   PubMedGoogle Scholar
• Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005;128:297-303
   PubMed Web of Science ®Google Scholar
• Corpechot C, Carrat F, Bonnand AM, et al. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000;32:1196-9
   PubMed Web of Science ®Google Scholar
• Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008;48:871-7
   PubMed Web of Science ®Google Scholar
• Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol 2010;52:745-58
   PubMed Web of Science ®Google Scholar
• Poupon R, Chretien Y, Poupon RE, et al. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987;1:834-6
   PubMed Web of Science ®Google Scholar
• Bachrach WH, Hofmann AF. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II. Dig Dis Sci 1982;27:833-56
   PubMed Web of Science ®Google Scholar
• Crosignani A, Setchell KD, Invernizzi P, et al. Clinical pharmacokinetics of therapeutic bile acids. Clin Pharmacokinet 1996;30:333-58
   PubMed Web of Science ®Google Scholar
• Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis 2004;8:67-81, vi
   PubMedGoogle Scholar
• Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012;36(Suppl 1):S3-12
   PubMed Web of Science ®Google Scholar
• Chazouilleres O, Marteau P, Haniche M, et al. Ileal absorption of bile acids in patients with chronic cholestasis: seHCAT test results and effect of ursodeoxycholic acid (UDCA). Dig Dis Sci 1996;41:2417-22
   PubMed Web of Science ®Google Scholar
• Lanzini A, De Tavonatti MG, Panarotto B, et al. Intestinal absorption of the bile acid analogue 75Se-homocholic acid-taurine is increased in primary biliary cirrhosis, and reverts to normal during ursodeoxycholic acid administration. Gut 2003;52:1371-5
   PubMed Web of Science ®Google Scholar
• Jazrawi RP, de Caestecker JS, Goggin PM, et al. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 1994;106:134-42
   PubMed Web of Science ®Google Scholar
• Beuers U, Spengler U, Zwiebel FM, et al. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease. Hepatology 1992;15:603-8
   PubMed Web of Science ®Google Scholar
• Arenas F, Hervias I, Uriz M, et al. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J Clin Invest 2008;118:695-709
   PubMed Web of Science ®Google Scholar
• Banales JM, Saez E, Uriz M, et al. Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology 2012;56:687-97
   PubMed Web of Science ®Google Scholar
• Gohlke H, Schmitz B, Sommerfeld A, et al. alpha5 beta1-integrins are sensors for tauroursodeoxycholic acid in hepatocytes. Hepatology 2013;57:1117-29
   PubMed Web of Science ®Google Scholar
• Guldutuna S, Zimmer G, Imhof M, et al. Molecular aspects of membrane stabilization by ursodeoxycholate [see comment]. Gastroenterology 1993;104:1736-44
   PubMed Web of Science ®Google Scholar
• Rodrigues CM, Fan G, Wong PY, et al. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med 1998;4:165-78
   PubMed Web of Science ®Google Scholar
• Mitsuyoshi H, Nakashima T, Sumida Y, et al. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun 1999;263:537-42
   PubMed Web of Science ®Google Scholar
• Rodriguez-Ortigosa CM, Cincu RN, Sanz S, et al. Effect of ursodeoxycholic acid on methionine adenosyltransferase activity and hepatic glutathione metabolism in rats. Gut 2002;50:701-6
   PubMed Web of Science ®Google Scholar
• Lapenna D, Ciofani G, Festi D, et al. Antioxidant properties of ursodeoxycholic acid. Biochem Pharmacol 2002;64:1661-7
   PubMed Web of Science ®Google Scholar
• Bernstein C, Payne CM, Bernstein H, Garewal H. Activation of the metallothionein IIA promoter and other key stress response elements by ursodeoxycholate in HepG2 cells: relevance to the cytoprotective function of ursodeoxycholate. Pharmacology 2002;65:2-9
   PubMed Web of Science ®Google Scholar
• Kawata K, Kobayashi Y, Souda K, et al. Enhanced hepatic Nrf2 activation after ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. Antioxid Redox Signal 2010;13:259-68
   PubMed Web of Science ®Google Scholar
• Okada K, Shoda J, Taguchi K, et al. Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice. Am J Physiol Gastrointest Liver Physiol 2008;295:G735-47
   PubMed Web of Science ®Google Scholar
• Koga H, Sakisaka S, Ohishi M, et al. Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Hepatology 1997;25:1077-84
   PubMed Web of Science ®Google Scholar
• Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991;324:1548-54
   PubMed Web of Science ®Google Scholar
• Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990;11:12-15
   PubMed Web of Science ®Google Scholar
• Tanaka H, Makino Y, Miura T, et al. Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway. J Immunol 1996;156:1601-8
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Hsu W, Hosoya N, et al. Ursodeoxycholic acid reduces CpG-induced IgM production in patients with primary biliary cirrhosis. Hepatol Res 2009;39:448-54
   PubMed Web of Science ®Google Scholar
• Yoshikawa M, Tsujii T, Matsumura K, et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992;16:358-64
   PubMed Web of Science ®Google Scholar
• Ishizaki K, Iwaki T, Kinoshita S, et al. Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein-2 production. Eur J Pharmacol 2008;578:57-64
   PubMed Web of Science ®Google Scholar
• Mattner J, Savage PB, Leung P, et al. Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe 2008;3:304-15
   PubMed Web of Science ®Google Scholar
• Nishigaki Y, Ohnishi H, Moriwaki H, Muto Y. Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis. Dig Dis Sci 1996;41:1487-93
   PubMed Web of Science ®Google Scholar
• Sasatomi K, Noguchi K, Sakisaka S, et al. Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 1998;29:409-16
   PubMed Web of Science ®Google Scholar
• Harada K, Nakanuma Y. Biliary innate immunity in the pathogenesis of biliary diseases. Inflamm Allergy Drug Targets 2010;9:83-90
   PubMedGoogle Scholar
• Ide T, Sata M, Nakano H, et al. Increased serum IgM class anti-lipid A antibody and therapeutic effect of ursodeoxycholic acid in primary biliary cirrhosis. Hepatogastroenterology 1997;44:1569-73
   PubMedGoogle Scholar
• Ballot E, Bandin O, Chazouilleres O, et al. Immune response to lipopolysaccharide in primary biliary cirrhosis and autoimmune diseases. J Autoimmun 2004;22:153-8
   PubMed Web of Science ®Google Scholar
• Schwarzenberg SJ, Bundy M. Ursodeoxycholic acid modifies gut-derived endotoxemia in neonatal rats. Pediatr Res 1994;35:214-17
   PubMed Web of Science ®Google Scholar
• Hori Y, Ohyanagi H. Protective effect of the intravenous administration of ursodeoxycholic acid against endotoxemia in rats with obstructive jaundice. Surg Today 1997;27:140-4
   PubMed Web of Science ®Google Scholar
• Miura T, Ouchida R, Yoshikawa N, et al. Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid. J Biol Chem 2001;276:47371-8
   PubMed Web of Science ®Google Scholar
• Shi J, Wu C, Lin Y, et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006;101:1529-38
   PubMed Web of Science ®Google Scholar
• Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 2007;102:1799-807
   PubMed Web of Science ®Google Scholar
• Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994;19:1149-56
   PubMed Web of Science ®Google Scholar
• Lindor KD, Therneau TM, Jorgensen RA, et al. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996;110:1515-18
   PubMed Web of Science ®Google Scholar
• Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-90
   PubMed Web of Science ®Google Scholar
• Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999;354:1053-60
   PubMed Web of Science ®Google Scholar
• Angulo P, Dickson ER, Therneau TM, et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999;30:830-5
   PubMed Web of Science ®Google Scholar
• Poupon RE, Lindor KD, Pares A, et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003;39:12-16
   PubMed Web of Science ®Google Scholar
• Lindor KD, Jorgensen RA, Therneau TM, et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997;72:1137-40
   PubMed Web of Science ®Google Scholar
• Huet PM, Vincent C, Deslaurier J, et al. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment. Gastroenterology 2008;135:1552-60
   PubMed Web of Science ®Google Scholar
• Combes B, Carithers RL Jr, Maddrey WC, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995;22:759-66
   PubMed Web of Science ®Google Scholar
• Poupon RE, Bonnand AM, Chretien Y, Poupon R. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology 1999;29:1668-71
   PubMed Web of Science ®Google Scholar
• Koulentaki M, Moscandrea J, Dimoulios P, et al. Survival of anti-mitochondrial antibody-positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment. Dig Dis Sci 2004;49:1190-5
   PubMed Web of Science ®Google Scholar
• ter Borg PC, Schalm SW, Hansen BE, van Buuren HR; Dutch PBCSG. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006;101:2044-50
   PubMed Web of Science ®Google Scholar
• Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006;130:715-20
   PubMed Web of Science ®Google Scholar
• Angulo P, Batts KP, Therneau TM, et al. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999;29:644-7
   PubMed Web of Science ®Google Scholar
• Locke GR III, Therneau TM, Ludwig J, et al. Time course of histological progression in primary biliary cirrhosis. Hepatology 1996;23:52-6
   PubMed Web of Science ®Google Scholar
• Corpechot C, Carrat F, Poupon R, Poupon RE. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002;122:652-8
   PubMed Web of Science ®Google Scholar
• Lee J, Belanger A, Doucette JT, et al. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007;5:1313-15
   PubMed Web of Science ®Google Scholar
• Corpechot C, Poupon R. Geotherapeutics of primary biliary cirrhosis: bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom. Hepatology 2007;46:963-5
   PubMedGoogle Scholar
• Kuiper EM, Hansen BE, Metselaar HJ, et al. Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008. BMC Gastroenterol 2010;10:144
   PubMed Web of Science ®Google Scholar
• Kuiper EM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009;136:1281-7
   PubMed Web of Science ®Google Scholar
• Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010;105:2186-94
   PubMed Web of Science ®Google Scholar
• Azemoto N, Kumagi T, Abe M, et al. Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis. Hepatol Res 2011;41:310-17
   PubMed Web of Science ®Google Scholar
• Silveira MG, Brunt EM, Heathcote J, et al. American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology 2010;52:349-59
   PubMed Web of Science ®Google Scholar
• Corpechot C, Carrat F, Poujol-Robert A, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012;56:198-208
   PubMed Web of Science ®Google Scholar
• Lindor KD, Gershwin ME, Poupon R, et al. American Association for Study of Liver D. Primary biliary cirrhosis. Hepatology 2009;50:291-308
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237-67
   PubMed Web of Science ®Google Scholar
• Hempfling W, Dilger K, Beuers U. Systematic review: ursodeoxycholic acid–adverse effects and drug interactions. Aliment Pharmacol Ther 2003;18:963-72
   PubMed Web of Science ®Google Scholar
• Siegel JL, Jorgensen R, Angulo P, Lindor KD. Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis. J Clin Gastroenterol 2003;37:183-5
   PubMed Web of Science ®Google Scholar
• Kuiper EM, Hansen BE, Lesterhuis W, et al. The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis. Clin Res Hepatol Gastroenterol 2011;35:29-33
   PubMed Web of Science ®Google Scholar
• Poupon R, Chretien Y, Chazouilleres O, Poupon RE. Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis. J Hepatol 2005;42:418-19
   PubMed Web of Science ®Google Scholar
• Kumagi T, Al-Harthy N, Coltescu C, Hirschfield GM. Pregnancy and primary biliary cirrhosis: cross-sectional and retrospective analyses demonstrate a high prevalence of symptoms and a risk of disease progression. Hepatology 2009;50:1008A
   Web of Science ®Google Scholar
• Leuschner M, Maier KP, Schlichting J, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999;117:918-25
   PubMed Web of Science ®Google Scholar
• Rautiainen H, Karkkainen P, Karvonen AL, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 2005;41:747-52
   PubMed Web of Science ®Google Scholar
• Rabahi N, Chretien Y, Gaouar F, et al. Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. Gastroenterol Clin Biol 2010;34:283-7
   PubMedGoogle Scholar
• Giljaca V, Poropat G, Stimac D, Gluud C. Methotrexate for primary biliary cirrhosis. Cochrane Database Syst Rev 2010;CD004385
   PubMed Web of Science ®Google Scholar
• Gong Y, Gluud C. Colchicine for primary biliary cirrhosis. Cochrane Database Syst Rev 2004;CD004481
   PubMed Web of Science ®Google Scholar
• Leung J, Bonis PA, Kaplan MM. Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 2011;9:776-80
   PubMed Web of Science ®Google Scholar
• Wiesner RH, Ludwig J, Lindor KD, et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med 1990;322:1419-24
   PubMed Web of Science ®Google Scholar
• Lombard M, Portmann B, Neuberger J, et al. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 1993;104:519-26
   PubMed Web of Science ®Google Scholar
• Silveira MG, Lindor KD. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents. Clin Liver Dis 2008;12:425-43; x-xi
   PubMed Web of Science ®Google Scholar
• Schaffner F. Paradoxical elevation of serum cholesterol by clofibrate in patients with primary biliary cirrhosis. Gastroenterology 1969;57:253-5
   PubMed Web of Science ®Google Scholar
• Summerfield JA, Elias E, Sherlock S. Effects of clofibrate in primary biliary cirrhosis hypercholesterolemia and gallstones. Gastroenterology 1975;69:998-1000
   PubMed Web of Science ®Google Scholar
• Lovett-Racke AE, Hussain RZ, Northrop S, et al. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol 2004;172:5790-8
   PubMed Web of Science ®Google Scholar
• Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 2007;28:551-8
   PubMed Web of Science ®Google Scholar
• Honda A, Ikegami T, Nakamuta M, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology 2013;57:1931-41
   PubMed Web of Science ®Google Scholar
• Iwasaki S, Ohira H, Nishiguchi S, et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol Res 2008;38:557-64
   PubMed Web of Science ®Google Scholar
• Komori A, Nakamura M, Aiba Y, et al. Who may have treatment benefits with fibrates in primary biliary cirrhosis: a single center retrospective observational cohort analysis. J Hepatol 2013;58:S387
   Web of Science ®Google Scholar
• Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002;45:3569-72
   PubMed Web of Science ®Google Scholar
• Song KH, Li T, Owsley E, et al. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 2009;49:297-305
   PubMed Web of Science ®Google Scholar
• Mason AL, Luketic VA, Lindor KD, et al. Farnesoid-X receptor agonists: a new class of drugs for the treatment of pbc? an inter- national study evaluating the addition of obeticholic acid (int-747) to ursodeoxycholic acid. Hepatology 2010;52:357A
   Web of Science ®Google Scholar
• Kowdley KV, Jones D, Luketic V, et al. An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in pbc. J Hepatol 2011;54:S13
   Web of Science ®Google Scholar
• Marschall HU, Luketic V, Lovgren-Sandblom A, et al. The farnesoid X receptor (FXR) agonist obeticholic acid (OCA) increases plasma FGF-19 concentrations and decreases bile acid synthesis in primary biliary cirrhosis (PBC). J Hepatol 2012;56:S377
   Web of Science ®Google Scholar
• Fickert P, Wagner M, Marschall HU, et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006;130:465-81
   PubMed Web of Science ®Google Scholar
• Denk GU, Maitz S, Wimmer R, et al. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver. Hepatology 2010;52:1758-68
   PubMed Web of Science ®Google Scholar
• Xu L, Shen Z, Guo L, et al. Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc Natl Acad Sci USA 2003;100:8454-9
   PubMed Web of Science ®Google Scholar
• Mason AL, Lindor KD, Bacon BR, et al. Clinical Trial: randomized controlled trial of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther 2008;28:886-94
   PubMed Web of Science ®Google Scholar
• MacQuillan GC, Neuberger J. Liver transplantation for primary biliary cirrhosis. Clin Liver Dis 2003;7:941-56; ix
   PubMedGoogle Scholar
• Schreuder TC, Hubscher SG, Neuberger J. Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far? Transpl Int 2009;22:144-52
   PubMed Web of Science ®Google Scholar
• Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int 2006;26:943-8
   PubMed Web of Science ®Google Scholar
• Tandon P, Rowe BH, Vandermeer B, Bain VG. The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 2007;102:1528-36
   PubMed Web of Science ®Google Scholar
• Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002;50:436-9
   PubMed Web of Science ®Google Scholar
• Bergasa NV. Pruritus in primary biliary cirrhosis: pathogenesis and therapy. Clin Liver Dis 2008;12:385-406; x
   PubMed Web of Science ®Google Scholar
• Kaplan MM, Bonis PA. Modafinil for the treatment of fatigue in primary biliary cirrhosis. Ann Intern Med 2005;143:546-7
   PubMed Web of Science ®Google Scholar
• Jones DE, Newton JL. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther 2007;25:471-6
   PubMed Web of Science ®Google Scholar
• Nakanuma Y, Harada K. The role of the pathologist in diagnosing and grading biliary diseases. Clin Res Hepatol Gastroenterol 2011;35:347-52
   PubMed Web of Science ®Google Scholar
• Poupon R, Chazouilleres O, Balkau B, Poupon RE. Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. UDCA-PBC Group. J Hepatol 1999;30:408-12
   PubMed Web of Science ®Google Scholar
• Kakuda Y, Harada K, Sawada-Kitamura S, et al. Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems. Hum Pathol 2013;44:1107-17
   PubMed Web of Science ®Google Scholar
• Baghdasaryan A, Claudel T, Gumhold J, et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO(-)(3) output. Hepatology 2011;54:1303-12
   PubMed Web of Science ®Google Scholar